Experience with the use of monoclonal antibodies, interleukin-6 inhibitors, in patients with a new coronavirus infection of medium degree of severity

In connection with the emergence of new, more aggressive strains of SARS-CoV-2, research aimed at creating the most effective strategies for the use of drugs that have already proven themselves in the treatment of COVID-19 and are registered for use in severe forms of this disease is of particular importance. The aim of this study was to analyze the experience of using monoclonal antibodies, interleukin-6 inhibitors, in adult patients with a moderate form of the new coronavirus infection. According to the results obtained, in the majority of patients with a moderate form of the new coronavirus infection with a threat of deterioration of the condition, the administration of monoclonal antibodies, interleukin-6 inhibitors, was effective in preventing the transition to a severe form. The drugs used in such clinical situations were olokizumab (artlegia) and levilimab (ilsira). The third drug studied in this research, tocilizumab (actemra), was used only for severe cases and when the condition worsened despite the administration of olokizumab. The results of the study show the actual possibility of using monoclonal antibodies, interleukin-6 inhibitors, in patients with a moderate form of COVID-19 in order to prevent the transition to a severe form and prove the need for further research to justify this approach.

1. Kaplon H., Reichert J.M. Antibodies to watch in 2021. MAbs, 2021, vol. 13(1), art. no. 1860476. doi: 10.1080/19420862.2020.1860476

2. Ghosn L., Chaimani A., Evrenoglou T., et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst. Rev., 2021, vol. 3(3), art. no. CD013881. doi: 10.1002/14651858.CD013881

3. Antonov V.N., Ignatova G.L., Pribytkova O.V., et al. Opyt primeneniya olokizumaba u patsiyentov s COVID-19 [Experience of olokizumab use in COVID-19 patients]. Terapevticheskiy arkhiv — Therapeutic Archive, 2020, vol. 92(12), pp. 148–154. doi: 10.26442/00403660.2020.12.200522

4. Richier Q., Plaçais L., Lacombe K., Hermine O. COVID-19: Still a place for tocilizumab? Rev. Med. Interne., 2021, vol. 42, iss. 2, pp. 73–78. doi: 10.1016/j.revmed.2020.11.016 (In French)

5. Lomakin N.V. Bakirov B.A., Protsenko D.N., et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflamm. Res., 2021, vol. 70(10-12), pp. 1233–1246. doi: https://doi.org/10.1007/s00011-021-01507-5